InsiderClue
Stocks · Health care · Pharmaceutical Preparations

GENELUX Corp

GNLX Clue Score27
United States Fiscal year ends December CIK 0001231457 Results filed 25 Mar 2025
Add to watchlist

What the insiders did Net selling

Individual transactions

10
Insider
Date
Role
Action
Shares
Price
Amount
Yong Yu
24 Oct 2023
VP, Clinical Trial Operations
Sold after exercise
5,200
$19.11
$99.35K
Yong Yu
10 Oct 2023
VP, Clinical Trial Operations
Sold after exercise
400
$22.91
$9.16K
Yong Yu
10 Oct 2023
VP, Clinical Trial Operations
Sold after exercise
4,800
$21.94
$105.30K
Yong Yu
26 Sep 2023
VP, Clinical Trial Operations
Sold after exercise
2,203
$24.46
$53.89K
Yong Yu
26 Sep 2023
VP, Clinical Trial Operations
Sold after exercise
1,114
$23.51
$26.20K
Yong Yu
26 Sep 2023
VP, Clinical Trial Operations
Sold after exercise
1,883
$22.54
$42.44K
Sean Ryder
20 Sep 2023
General Counsel
Sold after exercise
10,000
$30.00
$300.00K
Yong Yu
20 Sep 2023
VP, Clinical Trial Operations
Sold after exercise
6,000
$27.96
$167.79K
Yong Yu
15 Sep 2023
VP, Clinical Trial Operations
Sold after exercise
4,675
$22.29
$104.21K
Yong Yu
15 Sep 2023
VP, Clinical Trial Operations
Sold after exercise
5,725
$21.56
$123.42K
Show all 152 transactions →

What was left out

Form 4 filings counted 166
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 4
Sales straight out of an exercise 10
Sales at will 128
Transactions with no price 9
Shares from compensation/vesting 4,605,497
History held since 30 Jan 2023